Primary candidates for GLP-1 therapy include: Patients with type 2 diabetes and inadequate glycemic control despite metformin therapy Individuals with type 2 diabetes and established atherosclerotic cardiovascular disease Patients with type 2 diabetes and multiple cardiovascular risk factors (hypertension, dyslipidemia, obesity) Adults with obesity (BMI 30 kg/m) or overweight (BMI 27 kg/m) with weight-related comorbidities Patients with metabolic syndrome who have not achieved adequate risk factor control with lifestyle modification For patients with dyslipidemia, GLP-1 agents may be particularly valuable when combined with statin therapy in those who have not reached LDL-C goals or who have persistent hypertriglyceridemia despite statin treatment
Bolsters antioxidant action Promotes detoxification Fortifies the immune system What is liposomal glutathione
Atagun M, Atay OC, Balaban OD, Ipekcioglu D, Alpugan B, Yalcin S, Senat A, Karamustafalioglu N, Ilnem MC, Erel O
In summary, the overwhelming production of ROS during MIRI, coupled with the depletion, inactivation, and dysregulation of the intrinsic antioxidant defense mechanisms and their regulatory pathways, leads to a state of severe redox imbalance
Preclinical studies have demonstrated that ambroxol enhanced the antimycobacterial activity of rifampicin against intracellular BCG [27], induced autophagy through the activation of TFEB both in vitro and in vivo models, promoted mycobacterial killing in macrophages